Clinician-Guided Care
Every treatment plan is developed and monitored by licensed medical professionals to ensure safety, accuracy, and proper dosing.
+
+
.7★
GLP-1 treatments use a compound that mimics a natural hormone responsible for appetite regulation and glucose balance. They are prescribed by licensed clinicians when medically appropriate to support metabolic health.
These medications help slow digestion and promote a steadier release of energy, which can reduce appetite and improve consistency with healthy eating habits.
No. All evaluations, prescriptions, and follow-ups are handled through secure telehealth consultations with licensed medical providers.
Individual timelines vary. Many patients begin noticing changes in appetite or energy within several weeks as their body adjusts to treatment.
Invigor Medical offers compounded GLP-1 treatments prescribed when clinically appropriate and legally permissible. Compounded medications are not FDA-approved and do not undergo FDA premarket review.
These medications are not suitable for individuals with a history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), pancreatitis, or severe gastrointestinal disease.
Common effects may include mild nausea, constipation, or digestive discomfort as the body adjusts. Your provider will review potential risks before prescribing.
Our licensed clinicians provide ongoing monitoring, follow-up visits, and adjustments as needed to ensure your plan remains safe, effective, and aligned with your health goals.
Important Medication Info:
FDA-approved medications such as Saxenda®, Victoza®, Wegovy®, and Ozempic® are proprietary to Novo Nordisk™, while Mounjaro® and Zepbound™ are products of Eli Lilly and Company™. This website is not affiliated with, endorsed by, or associated with these companies or their products.
Invigor Medical does not supply FDA-approved branded medications. Instead, compounded alternatives may be prescribed when clinically appropriate and legally permissible. These medications are prepared by licensed 503A pharmacies in accordance with the Federal Food, Drug, and Cosmetic Act.
Compounded drugs are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality. They may be prescribed when commercially available products are unsuitable for an individual’s medical needs, but have not been evaluated by the FDA to confirm safety or efficacy for any specific use.
Important Medication Info:
FDA-approved medications such as Saxenda®, Victoza®, Wegovy®, and Ozempic® are proprietary to Novo Nordisk™, while Mounjaro® and Zepbound™ are products of Eli Lilly and Company™. This website is not affiliated with, endorsed by, or associated with these companies or their products.
Invigor Medical does not supply FDA-approved branded medications. Instead, compounded alternatives may be prescribed when clinically appropriate and legally permissible. These medications are prepared by licensed 503A pharmacies in accordance with the Federal Food, Drug, and Cosmetic Act.
Compounded drugs are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality. They may be prescribed when commercially available products are unsuitable for an individual’s medical needs, but have not been evaluated by the FDA to confirm safety or efficacy for any specific use.
Important Safety Information for GLP-1 Treatments
Compounded medications are legally prescribed under federal law but are not FDA-approved and have not undergone FDA review for safety, effectiveness, or manufacturing quality. The GLP-1 treatment available through Invigor Medical is prescribed based on an individualized medical evaluation by a licensed clinician.
WARNING: Risk of Thyroid C-Cell Tumors
In animal studies, GLP-1 receptor agonists have been associated with thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is not known whether these effects occur in humans. Inform your healthcare provider if you experience neck swelling, hoarseness, difficulty swallowing, or shortness of breath. GLP-1 treatments should not be used by individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not use GLP-1 treatments if:
Warnings and Precautions:
Pregnancy and Reproductive Health:
GLP-1 medications may cause harm to a fetus and should not be used during pregnancy or when planning to become pregnant. Discontinue at least two months before a planned pregnancy.
Common Side Effects:
Nausea, vomiting, diarrhea, constipation, abdominal discomfort, fatigue, and headache are the most commonly reported side effects.
Drug Interactions:
GLP-1 treatments may slow gastric emptying and affect the absorption of oral medications. Consult your healthcare provider for guidance on medication timing and adjustments.